andecaliximab + paclitaxel

**Andecaliximab + paclitaxel** is an experimental combination regimen involving andecaliximab, a humanized monoclonal antibody that selectively inhibits matrix metalloproteinase 9 (MMP9), and paclitaxel, a microtubule-stabilizing taxane-class chemotherapeutic agent. Andecaliximab binds to MMP9 at the junction between the propeptide and catalytic domains, thereby blocking activation and subsequent tumor-associated matrix remodeling, tumor growth, immune suppression, and metastasis. Paclitaxel promotes microtubule assembly and stabilizes microtubules by preventing their depolymerization, thereby inhibiting normal function of microtubule dynamics essential for mitosis, leading to cell cycle arrest and apoptosis[2][4][5][6]. The combination was studied preclinically and in clinical trials, often with additional cytotoxic agents in solid tumors like pancreatic adenocarcinoma[1][8]. The main purpose was to leverage the immunomodulatory and anti-metastatic effects of MMP9 blockade alongside the cytotoxicity of paclitaxel.

Other names

andecaliximabtaxol